Mock James M

Mock James M, Chief Financial Officer of Moderna (MRNA), has demonstrated a consistent pattern of selling activity in the company’s stock, with no recorded purchases across 28 transactions. Since August 2025, Mock has executed multiple sales totaling approximately $1.33 million, with the largest single transaction occurring on December 5, 2025, when shares worth $581,605 were sold. More recent dispositions include a $329,691 sale on March 5, 2026, and a $247,587 transaction on February 27, 2026, alongside smaller sales ranging from $4,001 to $19,944. The filings indicate these were primarily coded as "F" (tax liability or payment-for-feature transactions) rather than discretionary market sales. The transactions suggest a focus on periodic divestment rather than accumulation, with no offsetting buys reported during this period. While the sales are spread across multiple dates, the absence of any purchases—particularly for an executive in a high-growth biotech firm—stands out. The most recent activity in early March 2026 continues this trend, reinforcing a one-directional approach to equity management. All transactions relate exclusively to Moderna, with no diversification into other securities evident in the filings. The pattern aligns with routine executive stock sales, often tied to prearranged trading plans or tax obligations, though the filings do not specify the exact triggers.